Evidence map›Paper›PMID 37931533›Full record

ArticleNeurobiology of aging2024

Metformin, age-related cognitive decline, and brain pathology.

Ajay Sood, Ana Werneck Capuano, Robert Smith Wilson, Lisa Laverne Barnes, Alifiya Kapasi, David Alan Bennett, Zoe Arvanitakis

Open access · greenAbstract read
In one paragraph

Article in Neurobiology of aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease.Journal of cellular and molecular medicine · 2024
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ajay SoodRush Alzheimer's Disease Center, Chicago, IL, USA. Electronic address: Ajay_sood@rush.edu.
Ana Werneck CapuanoRush Alzheimer's Disease Center, Chicago, IL, USA.
Robert Smith WilsonRush Alzheimer's Disease Center, Chicago, IL, USA.
Lisa Laverne BarnesRush Alzheimer's Disease Center, Chicago, IL, USA.
Alifiya KapasiRush Alzheimer's Disease Center, Chicago, IL, USA.
David Alan BennettRush Alzheimer's Disease Center, Chicago, IL, USA.
Zoe ArvanitakisRush Alzheimer's Disease Center, Chicago, IL, USA.
Rush University · US

Funding

SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI ARFANAKIS, KONSTANTINOS · 1991 to 2020
$49.1M
EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
Rush Alzheimer's Disease Research CenterP30AG072975 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Lisa L Barnes, Julie A. Schneider · 2021 to 2026
$24.7M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Linking peripheral and brain insulin resistance to AD neuropathology and cognitionRF1AG059621 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI AHIMA, REXFORD S., ARNOLD, STEVEN E · 2018 to 2018
$3.8M
The role of blood and brain 5-hydroxymethylcytosine in linking vascular risk factors to ADRD in older White and Black personsRF1AG074549 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI ARVANITAKIS, ZOE · 2021 to 2021
$3.3M
Mechanisms linking insulin resistance to brain structure, pathology, and functionR01NS084965 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI AHIMA, REXFORD S., ARNOLD, STEVEN E · 2014 to 2018
$3.2M
The role of blood and brain 5-hydroxymethylcytosine in linking vascular risk factors to ADRD in older White and Black personsR01AG074549 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI ARVANITAKIS, ZOE · 2024 to 2025
$2.2M
NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG072975NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG074549NIA NIH HHS RF1 AG059621NIA NIH HHS RF1 AG074549NINDS NIH HHS R01 NS084965
6 · The paper itself

Abstract

The objective of this study was to evaluate the relation of metformin with change in cognition and brain pathology. During a mean of 8 years (SD = 5.5) of annual follow-up visits, 262/3029 participants were using metformin at any time during the study. Using a linear-mixed effect model adjusted for age, sex, and education, metformin users had slower decline on a score of global cognition compared to non-users (estimate = 0.017, SE = 0.007, p = 0.027). Analyses of cognitive domains showed a slower decline in episodic memory and semantic memory specifically. In sensitivity analysis, when examining any diabetes medication use vs none, no association was observed of any diabetes medication use with cognitive function. In the autopsy subset of 1584 participants, there was no difference in the level of Alzheimer's disease (AD) pathology or the presence of infarcts (of any size or location) between groups of metformin users vs non-users. However, in additional analyses, metformin users had higher odds of subcortical infarcts, and lower odds of atherosclerosis and arteriosclerosis.

Indexed as

Alzheimer DiseaseCognitive DysfunctionDiabetes MellitusMemory, EpisodicMetforminBrainCerebral InfarctionCognitionHumansNeuropsychological TestsMetforminAlzheimer’s diseaseAtherosclerosisBrain infarctCognitionDiabetesMetformin

Identifiers

PMID37931533
PMCPMC10841359
OpenAlexW4387709556

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.